TSX gains on big banks strength
ST. LOUIS - Stereotaxis, Inc. (NYSE:STXS), a surgical robotics company focused on minimally invasive endovascular intervention, announced Thursday it has secured approximately $12.5 million through a registered direct offering of common stock. The company, currently valued at $205 million, trades near $2.39 per share, with InvestingPro analysis indicating the stock is fairly valued.
The company is selling shares at $2.00 each to a group of investors led by a strategic industry partner alongside select institutional investors. The transaction will occur in two closings, with an initial $8.5 million expected to close on or about July 18, followed by a second $4.0 million closing scheduled on or before November 25, 2025. With a gross profit margin of 53.4% and moderate debt levels, InvestingPro data shows the company maintains stable operational metrics despite not being profitable in the last twelve months.
"We appreciate the support of our strategic partner and institutional investors in this offering, the proceeds from which will be used to accelerate product commercialization in this milestone rich year, as well as for research and development and other corporate purposes," said David Fischel, Chairman and CEO of Stereotaxis.
Lake Street Capital Markets LLC is serving as the exclusive placement agent for the offering, which is being conducted under a shelf registration statement previously filed with the SEC.
Stereotaxis describes itself as a pioneer in surgical robotics for minimally invasive endovascular procedures. According to the company, its technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. Analysts maintain optimistic price targets between $4-$5 per share, with the next earnings report scheduled for August 7, 2025. Get deeper insights and exclusive analysis with InvestingPro’s comprehensive research report, one of 1,400+ available for top US stocks.
The announcement was made in a press release statement issued by the company.
In other recent news, Stereotaxis Inc. reported its first-quarter financial results for 2025, meeting Wall Street expectations with an earnings per share (EPS) of -0.07, aligning with forecasts. The company recorded revenue of $7.5 million, surpassing the expected $6.83 million, marking a 9% year-over-year growth. Additionally, Stereotaxis received European approval for its MAGIC RF Ablation Catheter, which has been adopted in 20% of European hospitals. In corporate governance developments, Stereotaxis held its Annual Meeting of Shareholders, where two Class III directors, Dr. Nathan Fischel and Mr. Ross B. Levin, were elected, and Ernst & Young LLP was ratified as the independent auditor for 2025.
Analysts from firms like Piper Sandler and Lake Street Capital Markets have shown interest in the company’s strategic advancements, though there have been no recent upgrades or downgrades reported. Stereotaxis’ strategic focus on expanding its product line and securing regulatory approvals appears to be yielding results, with significant contributions from both system and recurring revenues. The company anticipates double-digit revenue growth throughout 2025, driven by its expanding product portfolio and strategic market initiatives. These developments reflect the company’s ongoing efforts to strengthen its market position and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.